Profil de l'entreprise · Healthcare

Becton Dickinson and Company

BDX · États-Unis
Bourse
États-Unis
Pays / Région
USA
Date d'introduction en bourse
1 janvier 1987
Effectif
60 000
Site web
www.bd.com
Cours actuel
$143.98
En direct · 18 juin 2026
Score de croissance Baillie
40/100
Faible
Valeur intrinsèque · Fourchette en trois niveaux Cours actuel $143.98 En direct · Entre la fourchette prudente et la fourchette raisonnable

Fourchette de valorisation composite · prudent $108–$125 / raisonnable $154–$178 / optimiste $217–$249. À $143.98, Entre la fourchette prudente et la fourchette raisonnable.

À la publication $147.63 (24 mai 2026)

Pas encore d'analyse sur cette valeur dans votre langue.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

Capitalisation39,02 Md $US
Chiffre d'affaires (TTM)22,23 Md $US
EBITDA6,16 Md $US
Marge nette5,12 %
ROE6,67 %
PER (TTM)24,71
PER prévisionnel10,49
PEG1,11
BPA5,73 $US
Rendement du dividende2,88 %
Fourchette sur 52 semaines125,21 $US – 184,86 $US
Objectif de cours des analystes180,69 $US
Recommandation des analystes3.8 / 5

Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.

Historique

Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.

Position dans le secteur

Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.